Ozempic Shortage Guide for Healthcare Providers: Alternatives, Switching Protocols, and Patient Communication

The Ozempic shortage has created real clinical headaches for prescribers managing patients with type 2 diabetes and obesity-related comorbidities. This guide covers the current shortage landscape, evidence-based switching protocols, prior authorization strategies, and how to leverage FindUrMeds as a practical resource to reduce the administrative burden on your practice.

---

The Current Ozempic Shortage: What Prescribers Need to Know

Ozempic (semaglutide injection) has experienced on-and-off supply constraints since 2022, driven by a surge in demand that significantly outpaced Novo Nordisk's manufacturing capacity. While the FDA removed semaglutide from its official drug shortage database in 2024 following capacity expansions, availability remains inconsistent at the pharmacy level — particularly for the 0.5 mg and 1 mg dose strengths.

In practice, this means your patients may be calling your office unable to fill their prescription even when the drug is technically "not in shortage." Regional distribution gaps, individual pharmacy stocking decisions, and high local demand continue to create access problems that fall squarely on your team to manage.

For patients using Ozempic specifically for glycemic control in type 2 diabetes — as opposed to Wegovy for weight management — the stakes are high. Disruptions in GLP-1 therapy can lead to worsening HbA1c, patient frustration, and increased utilization of other healthcare resources.

---

Therapeutic Alternatives: What to Consider When Ozempic Isn't Available

When a patient cannot access Ozempic, your first step is evaluating whether another GLP-1 receptor agonist or alternative antidiabetic agent is clinically appropriate. Here's a practical framework.

Other GLP-1 Receptor Agonists

Trulicity (dulaglutide) — A once-weekly injectable GLP-1 agonist with a well-established efficacy and safety profile. Cardiovascular outcome data (REWIND trial) support its use in patients with or at risk for cardiovascular disease. May be more readily available in some regions.

Victoza (liraglutide) — A once-daily injectable GLP-1 agonist. Longer track record in clinical practice. Cardiovascular benefit established in the LEADER trial. Less convenient dosing than once-weekly options but may be accessible when weekly formulations are not.

Rybelsus (oral semaglutide) — The oral formulation of semaglutide, same active molecule as Ozempic. Availability has generally been less affected by the same supply pressures. For patients who are already tolerating semaglutide well, this is often the most clinically straightforward bridge — though bioavailability differences require dose recalibration. Absorption is sensitive to food and water timing, so patient education is essential.

Mounjaro / Zepbound (tirzepatide) — A dual GIP/GLP-1 receptor agonist with robust glycemic and weight loss efficacy data. Mounjaro is FDA-approved for type 2 diabetes; Zepbound for chronic weight management. Has experienced its own supply fluctuations but may be available when semaglutide is not. Notably potent — patients switching from Ozempic may experience different tolerability profiles.

Byetta / Bydureon BCise (exenatide) — Older GLP-1 agents with more modest efficacy data relative to newer options. May serve as a short-term bridge when other options are unavailable.

Non-GLP-1 Alternatives

When no GLP-1 agent is accessible or covered, consider the patient's full clinical picture:

• SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) — Complementary mechanism, with established cardiovascular and renal protective benefits. A strong second-line choice in patients with heart failure or CKD.
• DPP-4 inhibitors (sitagliptin, linagliptin) — Well-tolerated, lower efficacy ceiling, but useful as a bridge in patients who cannot tolerate injectables or need something immediately accessible.
• Basal insulin — Appropriate in patients with significant hyperglycemia who need rapid glycemic stabilization while GLP-1 access is restored.

---

Switching Protocols: Clinical Considerations

Switching between GLP-1 agents is generally feasible but requires attention to a few key variables.

Dose equivalency is not 1:1 across agents. Semaglutide is significantly more potent on a per-molecule basis than older GLP-1s like liraglutide or exenatide. When switching down in potency, patients may experience worsening glycemic control. Set expectations clearly and plan for a follow-up HbA1c or fasting glucose check within 4–8 weeks.

GI tolerability varies. Nausea, vomiting, and GI discomfort are class effects, but their severity differs across agents and individuals. Patients well-adapted to semaglutide may experience a new wave of GI side effects when starting a structurally different GLP-1. A slow titration approach is advisable when switching — don't assume prior GLP-1 tolerance equals full cross-agent tolerance.

Injection device differences matter. Ozempic uses a pre-filled pen with specific administration steps. Trulicity uses an auto-injector; Victoza uses a different pen system. Patients will need retraining on device use. If your office can provide even brief verbal instruction or printed materials, it significantly reduces call-backs and errors.

Timing of the switch. For once-weekly agents, the switch can generally occur at the patient's next scheduled injection date. For patients switching from a weekly to a daily agent, start the daily agent the day after the last weekly dose would have been administered.

Document the switch thoroughly. Note the reason for switching (shortage-related), the new agent and dose, and your monitoring plan. This documentation will support prior authorization appeals if needed.

---

Prior Authorization Considerations

One of the more time-consuming aspects of shortage-related switching is prior authorization. Here's how to approach it efficiently.

For alternative GLP-1 agents: Many payers that cover Ozempic will require a new PA for a different GLP-1. Frame your appeal around medical necessity due to documented shortage-related unavailability. Use language like "unable to obtain at any in-network pharmacy" and attach any documentation of failed fill attempts if available.

Step therapy exceptions: Some payers require step therapy through older agents before approving a branded GLP-1. For patients already established on Ozempic, a shortage-driven switch may qualify for a step therapy exception. Most states have enacted step therapy exception laws — know your state's requirements.

Manufacturer assistance programs: Novo Nordisk offers savings cards and patient assistance for Ozempic. Eli Lilly has similar programs for tirzepatide. For uninsured or underinsured patients, these can make a significant difference — [see our companion guide on helping patients save money on Ozempic → ARTICLE 12].

Expedited PA requests: When a patient is at clinical risk due to lack of access — particularly those with elevated baseline HbA1c or recent cardiovascular events — request expedited review and note the urgency explicitly.

---

Communicating With Patients About Shortages

How you communicate shortage situations to patients significantly affects their trust, adherence, and anxiety levels. A few principles that work in practice:

Be direct and validating. Patients often feel like they're being told "the medication exists, you just can't have it." Acknowledge that this is genuinely frustrating and that you're advocating for them, not just redirecting them.

Explain the "why" briefly. Most patients respond better when they understand the shortage is a supply chain issue, not a formulary decision made by their insurance company or your office. A sentence or two is enough.

Give them a clear next step. Ambiguity increases anxiety. Tell them specifically what you're doing — whether that's calling in an alternative, submitting a PA, or directing them to a pharmacy locator service — and give them a realistic timeframe.

Reassure them about bridging options. If you're prescribing a temporary alternative, emphasize that it's an evidence-based medication and that your goal is to return to their usual regimen when it's available. Patients who feel like they're getting a "lesser" medication are more likely to skip doses.

Set up a follow-up touchpoint. A quick nurse call or portal message within 1–2 weeks of a switch allows you to catch tolerability issues early and reinforces that your team is actively managing their care.

---

Using FindUrMeds as a Provider Resource

When patients are having trouble locating Ozempic or an alternative in stock, FindUrMeds can significantly reduce the burden on your office staff.

Rather than having your MA or front desk call pharmacy after pharmacy, FindUrMeds contacts pharmacies directly on behalf of the patient, searching across 15,000+ locations nationwide — including CVS, Walgreens, Rite Aid, Walmart, Kroger, Publix, Costco, and Sam's Club — and typically identifies in-stock locations within 24–48 hours.

For providers, this means:

• Fewer "we can't find it" calls back to your office
• Less administrative time spent on shortage triage
• Patients who feel supported and are more likely to stay adherent
• A clear resource you can recommend by name during the visit or in after-visit summaries

You can direct patients to findurmeds.com or refer to our companion article on [how to help patients find Ozempic in stock → ARTICLE 11] for patient-facing guidance you can share directly.

FindUrMeds is particularly useful for patients in rural areas with fewer pharmacy options, patients with mobility limitations who can't call around themselves, and practices with high patient volume where staff shortage triage isn't scalable.

---

A Note on Compounded Semaglutide

During the peak shortage period, compounded semaglutide became widely available through compounding pharmacies and telehealth platforms. As of 2025, the FDA's removal of semaglutide from the shortage list has prompted regulatory action against most compounded versions — major compounding pharmacies have been required to cease production.

The clinical and regulatory landscape here is still evolving. If patients ask about compounded semaglutide, acknowledge that FDA-approved options should be the priority, and note that purity, potency, and sterility standards for compounded versions are not held to the same regulatory standard as branded products. Refer to current FDA guidance for the most up-to-date enforcement posture.

---

Quick Reference: Ozempic Shortage Action Checklist

• Confirm shortage at local pharmacies before switching
• Evaluate clinical suitability for alternative GLP-1 or non-GLP-1 agent
• Review payer formulary for covered alternatives
• Submit PA or step therapy exception if required
• Counsel patient on new agent and device training
• Schedule follow-up in 4–8 weeks post-switch
• Direct patient to FindUrMeds if continuing to search for Ozempic
• Document shortage-related switch thoroughly in the chart

---

Frequently Asked Questions

Can patients switch directly from Ozempic to oral semaglutide (Rybelsus) without a washout period?

Yes, generally. Since both contain semaglutide, there's no washout required. The primary consideration is dosing: oral semaglutide has lower bioavailability than the injectable formulation, so dose conversion isn't linear. Most clinical guidance suggests starting Rybelsus at 7 mg daily for patients bridging from low-dose Ozempic and titrating based on response. Confirm with current prescribing information and use clinical judgment based on the patient's prior dose and glycemic status.

How should I document a shortage-related medication switch for insurance purposes?

Document that the brand-name medication was unavailable at pharmacies in the patient's area, note the clinical rationale for the alternative selected, and include any failed fill attempts if the patient has them. Use the phrase "drug shortage" explicitly in your note. This documentation supports PA appeals and protects continuity of care records if the patient's care is transferred.

Are there cardiovascular outcome differences between Ozempic and its alternatives that I should factor into switching decisions?

Yes, and this matters clinically. Semaglutide (SUSTAIN-6, SELECT), liraglutide (LEADER), and dulaglutide (REWIND) all have positive CVOT data, though trial populations and endpoints differ. Exenatide extended-release demonstrated noninferiority but not superiority in EXSCEL. Tirzepatide's cardiovascular outcome data is still maturing. For patients with established ASCVD or high CV risk, prioritize agents with proven cardiovascular benefit when selecting an alternative.

Should I be concerned about patients seeking compounded semaglutide on their own?

Yes, this warrants a direct conversation. Compounded semaglutide products are not FDA-approved, are not subject to the same manufacturing standards, and may carry risks related to inaccurate dosing or contamination. With semaglutide now off the FDA shortage list, compounding of copies of the branded product is no longer legally permitted at most facilities. If a patient is currently using a compounded version, discuss transitioning to an FDA-approved alternative and monitor accordingly.

---

Need help finding Ozempic in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.

Find Ozempic Near You →

---

FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.

About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →